Key points
- The brain keeps developing into young adulthood, until about age 21. Regular cannabis use during this phase is associated with more risks than in adults.
- In a New Zealand long-term study, persistent use that began in adolescence was associated with a decline in mental performance up to the age of 38.
- Among young people with weekly or daily use, around one third developed dependence in cohort studies.
- In a meta-analysis, heavy use was associated with an almost fourfold increased risk of psychosis. Adolescent use is also linked to more depression and suicidal thoughts.
- This article is intended for prevention. It contains no treatment recommendations for minors.
Cannabis is riskier for adolescents than for adults. The brain keeps developing into young adulthood, until about age 21, and the body’s own endocannabinoid system is involved in this development. Experts assume that THC can have a stronger and more lasting effect during this phase. Studies show a higher risk of dependence, reduced performance and mental illness with early and regular use.1
This article is intended for prevention and information. It gives no advice on treating minors with cannabis. The risks depend on the age at first use, the frequency and the strength of the cannabis. Occasional use is not the same as daily use, but there is no safe level for adolescents.1,3
Why the adolescent brain is particularly sensitive
In adolescence the brain is restructured: connections are strengthened or pruned, and areas for planning, impulse control and memory mature last. A review in the New England Journal of Medicine describes how the endocannabinoid system is involved in these processes. Anyone who regularly takes THC during this time interferes with a system that is currently steering development.1
The authors point out that imaging studies in people with early, regular use showed changes in brain regions important for learning and memory. Such studies cannot always clarify whether cannabis is the cause or whether existing differences favour use.1
Cannabis in adolescents: memory, concentration and school
One of the most meaningful studies comes from New Zealand. The Dunedin study followed 1037 people from birth to the age of 38. Mental performance was tested at age 13, that is, before first use, and again at age 38.2
Persistent cannabis use was associated with a decline in several areas, even when years of education were taken into account. The losses mainly affected people who had already used regularly in adolescence. The longer use continued, the greater the decline. In these people, stopping later did not fully restore performance.2
This study, too, is observational. It is nonetheless a strong signal because performance before the start of use was known.2
Risk of dependence: the earlier, the higher
Cannabis can be addictive. A meta-analysis of 21 studies found that among people who use cannabis, around 22 per cent have a cannabis use disorder and around 13 per cent have dependence. Among young people with weekly or daily use, the risk of dependence in cohort studies was about 33 per cent.3
33 %
The authors stress that the risk is particularly high with early onset and frequent use in adolescence. Signs of dependence include use that is hard to control, crowds out other interests or continues despite problems.3
Psychosis risk: how strong the association is
A meta-analysis of ten studies with over 66,000 people found a clear association between the amount used and the risk of psychosis. In people with the heaviest use, the risk of schizophrenia and similar illnesses was almost four times as high as in people who did not use. This does not definitively prove causation, but the researchers consider prevention justified.4
In a European case-control study, daily use was associated with an about threefold increased risk of a first psychosis, and daily use of high-THC cannabis with an almost fivefold risk. The study also shows that more psychoses occur where strong cannabis is widespread.5
Young people with a family history of psychosis are at particular risk. Anyone who experiences mistrust, hearing voices or severe confusion after cannabis should seek medical help quickly.1,5
Depression, anxiety and suicidal thoughts
A meta-analysis of eleven long-term studies with over 23,000 people examined adolescents who had used cannabis before the age of 18. In young adulthood they more often had depression and more often had suicidal thoughts and suicide attempts than peers who had not used. For anxiety disorders, the analysis found no clear association.6
The authors described the individual risk as moderate to low. However, because many adolescents use cannabis, the total number of people affected can be significant.6
Prevention: what parents and professionals can do
A large review of prevention in young people found that merely providing information at school achieves little. Programmes that train life skills, such as dealing with peer pressure and stress, performed better. For brief interventions, the evidence in adolescents was limited.7
For parents this means: an open, calm conversation is usually more helpful than threats. Ask about reasons, such as stress, sleep problems or pressure in the group. If there are signs of frequent use, social withdrawal or declining performance, the family doctor, addiction counselling services and school counselling services are first points of contact. Use sometimes masks untreated problems such as anxiety, depression or ADHD, which should be assessed by a professional.
Keep cannabis products, including prescribed ones, out of reach of children and adolescents. Read more about the mental health side in the article Cannabis medicine despite pre-existing mental illness?, about side effects in Cannabis side effects and on the overview page Safety.
How it works at evidena
At evidena, a doctor assesses the risks before every prescription. Whether a therapy can be considered is decided individually by the doctor, and pre-existing mental illness and age are among the most important points of this assessment. If a prescription is issued, it must be filled at a pharmacy within one month. As a rule, the prescribed quantity covers one month, in justified cases at most three months of treatment.8 You can book appointments at portal.evidena.care. We answer questions via WhatsApp or at info@evidena.care. Answers to frequently asked questions can be found in the FAQ.
Conclusion
For adolescents, cannabis is associated with considerably more risks than for adults. Studies show a higher risk of dependence, psychosis, depression and reduced mental performance with early and regular use. Most data are observational, but they point in the same direction. The later and less often cannabis is used, the lower the known risks.2,3,4
This article is for general information and does not replace individual medical advice.
Frequently asked questions
Why is cannabis more dangerous for adolescents than for adults?
The brain matures into young adulthood, until about age 21, and the endocannabinoid system is involved in this maturation. Studies show a higher risk of dependence, psychosis and reduced performance with early and regular use.
How high is the risk of becoming dependent?
In a meta-analysis, 13 per cent of people who used cannabis developed dependence. Among young people with weekly or daily use, it was around 33 per cent.
Can cannabis trigger psychosis?
In studies, heavy and daily use is clearly associated with psychosis, especially with high-THC cannabis. People with a family history of psychosis are at particular risk.
Does evidena prescribe cannabis to adolescents?
This article is intended for prevention and gives no treatment advice for minors. The treatment of children and adolescents belongs in the hands of specialised doctors.
Where can adolescents and parents find help?
First points of contact are the family doctor, addiction counselling services and school counselling services. In a mental health crisis, Die Dargebotene Hand can be reached on 143, and in an emergency the ambulance service on 144.
Sources
- Volkow ND et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–2227. doi:10.1056/NEJMra1402309
- Meier MH et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–E2664. doi:10.1073/pnas.1206820109
- Leung J et al. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addict Behav. 2020;109:106479. doi:10.1016/j.addbeh.2020.106479
- Marconi A et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016;42(5):1262–1269. doi:10.1093/schbul/sbw003
- Di Forti M et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–436. doi:10.1016/S2215-0366(19)30048-3
- Gobbi G et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(4):426–434. doi:10.1001/jamapsychiatry.2018.4500
- Stockings E et al. Prevention, early intervention, harm reduction, and treatment of substance use in young people. Lancet Psychiatry. 2016;3(3):280–296. doi:10.1016/S2215-0366(16)00002-X
- Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, Art. 47, Stand am 23. Januar 2023, Fedlex (accessed 13 November 2026)